Inside Oncology Drug Development: Overcoming Resistance with Science

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that resistance often leads to disease relapse, severely impacting patient outcomes and quality of life.

As we develop increasingly precise and powerful cancer therapies, how can we anticipate and overcome the inevitable challenge of drug resistance?

In this episode of Crowncast, host Jonny McMichael, VP of Client Experience & Enablement at Crown BioScience, speaks with Enrico Pesenti, the company’s Executive Director of Client Engagement. Together, they explore the evolving landscape of oncology drug resistance—unpacking the biological mechanisms behind it, the impact on patient care, and the technological breakthroughs helping researchers counter it.

Main Points:

  • Resistance in cancer therapy emerges through both genetic mutations and adaptive, non-genetic mechanisms, presenting a dynamic challenge for drug developers.

  • New technologies—such as single-cell multi-omics, spatial transcriptomics, and CRISPR gene editing—are enabling deeper understanding and more precise modeling of resistance pathways.

  • Translational models like organoids and patient-derived xenografts, combined with AI and machine learning, are helping design better, more personalized therapeutic strategies.

Enrico Pesenti brings over two decades of experience in oncology research and drug development. He previously held leadership roles at Pharmacia and Nerviano and served as CEO of Accelera, a regulatory CRO in Italy. At Crown BioScience, he leads scientific engagement, drawing on deep expertise in pharmacology and personalized cancer therapies.

Recent Episodes

Healthcare systems continue to face intense workforce challenges, with nursing at the center of concern. According to the U.S. Bureau of Labor Statistics, employment of registered nurses is expected to grow 5% between 2024 and 2034—faster than the average growth across all jobs in the U.S. economy. While this growth reflects rising demand for…

In this episode of Care Anywhere: The Global Health Workforce Podcast, host Lea Sims, Chief Marketing Officer of TruMerit, welcomes Kathryn Shaffer, EdD, RN, MSN, CNE, CCFP, Director of Innovation at Thomas Jefferson University’s College of Nursing. Kathryn brings a distinctive perspective on reimagining nursing education and practice through a holistic, self-healing lens. The…

The landscape of employee benefits has undergone a seismic shift in the last decade. From the rise of telemedicine to the introduction of lifestyle spending accounts and stipends for services like DoorDash and HelloFresh, employers are reimagining how they support workers in a post-pandemic, inflation-conscious world. With healthcare costs rising and talent competition intensifying,…